AFP DEPARTMENT COLLECTION

STEPS

This department includes information about new drugs from the perspective of the five attributes to be considered when weighing the advantages of one drug over another: Safety, Tolerability, Effectiveness, Price, and Simplicity.

Sep 01, 2021 Issue
Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients
Although remdesivir has been shown to be safe and well tolerated, there is a lack of consistency in clinical trial results and guideline recommendations.


Jul 01, 2021 Issue
Clascoterone (Winlevi) for the Treatment of Acne
More comparative data are needed to justify the use of clascoterone over less expensive, currently available therapies for moderate to severe acne. However, systemic absorption of clascoterone is low, and it may serve as a safe alternative for patients 12 years and older who saw improvements from oral antiandrogen therapy but could not tolerate systemic adverse effects such as blood pressure changes or gynecomastia.


May 15, 2021 Issue
Lactic Acid, Citric Acid, and Potassium Bitartrate (Phexxi) Vaginal Gel for Contraception
Given its high cost, mediocre contraceptive protection, and rate of adverse effects, Phexxi may be preferred only by people desiring to avoid hormonal contraception who wish to use on-demand contraception that they control, or for whom other contraceptive options are not suited or desired.


Apr 15, 2021 Issue
Elagolix, Estradiol, and Norethindrone Kit (Oriahnn) for the Management of Heavy Menstrual Bleeding Associated with Fibroids
Oriahnn can decrease menstrual blood loss in premenopausal patients with uterine fibroids. Although it has been studied for only six months of use and may result in significant bone loss, it is labeled for up to two years of continuous therapy.


Mar 15, 2021 Issue
Bempedoic Acid (Nexletol) for the Treatment of Hyperlipidemia and Familial Hypercholesterolemia
Bempedoic acid is labeled as add-on therapy to diet and maximally tolerated statin for the treatment of familial hypercholesterolemia or atherosclerotic cardiovascular disease.


Feb 15, 2021 Issue
Lemborexant (Dayvigo) for the Treatment of Insomnia
Lemborexant (Davigo) is labeled for adults with insomnia to improve with sleep onset and maintenance.


Jan 15, 2021 Issue
Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke
Icosapent ethyl is safe, well tolerated and effective in preventing ischemic events including stroke and heart attack.


Dec 15, 2020 Issue
Lasmiditan (Reyvow) for the Treatment of Acute Migraine
Lasmiditan is a costly alternative to other more extensively studied medications for acute migraine. It should be reserved for those patients who lack relief with other available agents or who cannot tolerate other abortive medications.


Nov 15, 2020 Issue
Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus
Oral semaglutide (Rybelsus) is labeled as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus


Oct 15, 2020 Issue
Trifarotene (Aklief) for the Treatment of Acne
Trifarotene is a monotherapy option for acne affecting the face and trunk and offers an alternative to topical antibiotics or anti-inflammatory agents for the management of moderate inflammatory and noninflammatory acne.


Pages: 1 2 3 4 5 6 7 8 9 10 ... 16 Next


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now